BIO:ON Insight #10 · Jul 28, 2026
Drugs keep getting more complex. So why is treatment getting easier?
Lilly's triple agonist retatrutide cuts weight by up to 22.6%, J&J's two-bispecific combo lowers myeloma progression risk by 89%, and Merck builds supply for a monthly HIV prevention pill before approval. Drugs keep getting more complex, so why is treatment getting easier?
What I learned this week
If I had to sum up this week in one line: complexity isn't removed, it's moved. When something gets easier for patients, somewhere inside the company it got harder. Ask "what did they make harder so this could get easier?" and you'll see a lot more in every biotech headline. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Clinical Trials
Lilly's retatrutide Phase 3: 22.6% weight loss
Eli Lillyretatrutide
- Clinical Trials
J&J's Tecvayli–Talvey combo cuts multiple myeloma progression risk by 89%
Johnson & JohnsonTecvayli & Talvey
- Market Trends
Merck's once-monthly oral HIV prevention alimatravir: early supply strategy
Merck & Co.alimatravir
AI summary
- 1Lilly's triple agonist retatrutide cut body weight by up to 22.6% in Phase 3.
- 2A J&J two-bispecific combo lowered multiple myeloma progression risk by 89% — an off-the-shelf alternative to CAR-T.
- 3Merck laid out a plan to start supplying its once-monthly oral HIV prevention pill before approval.
Relevant rolesClinical developmentMarket accessCMC & QA
Summary and tags generated by AI from the issue text.
References
- 1.Lilly's triple agonist retatrutide Phase 3 data — 22.6% weight loss (opens in a new tab)
Fierce Biotech / Clinical Trials Arena, Jul 23, 2026
- 2.J&J's Tecvayli–Talvey bispecific combo cuts myeloma progression risk by 89% (opens in a new tab)
Fierce Pharma, Jul 23, 2026
- 3.Merck's monthly oral HIV prevention pill alimatravir — early supply strategy (opens in a new tab)
Fierce Pharma, Jul 24, 2026
Related insights
Other issues covering the same companies, drugs or topics